Rimonabant (SR141716): Precision Tools for Appetite and Withdrawal Research

Principle Overview: Rimonabant as a Selective Endocannabinoid System Modulator

Rimonabant (SR141716) is a highly selective antagonist of the central cannabinoid receptor CB1, exhibiting over 285-fold selectivity for CB1 versus CB2 receptors, with a reported Ki of 1.8 nM for CB1 (product information). By competitively inhibiting CB1 receptor activity, Rimonabant acts as a potent endocannabinoid system modulator, disrupting signaling pathways that regulate appetite, reward, and metabolic homeostasis. Its well-characterized pharmacology makes it the gold-standard tool for dissecting CB1-mediated behaviors—including feeding, addiction, and withdrawal—in both in vitro and in vivo models.

Importantly, Rimonabant's competitive blockade of CB1 enables researchers to interrogate the functional consequences of endocannabinoid signaling, offering clear readouts in appetite regulation research, anti-obesity compound screening, and withdrawal paradigms. Its solubility profile (≥23.19 mg/mL in DMSO, ≥57.1 mg/mL in ethanol, insoluble in water) and stability at -20°C ensure compatibility with diverse experimental workflows.

Step-by-Step Experimental Workflow: Maximizing Rimonabant's Utility

Applied research with Rimonabant (SR141716) spans a spectrum from acute in vitro assays to complex in vivo behavioral models. Below is an optimized workflow for leveraging Rimonabant in appetite and withdrawal studies, drawing on both manufacturer recommendations and contemporary literature.

Protocol Parameters

• Solution preparation: Dissolve Rimonabant at 10–50 mg/mL in 100% DMSO or ethanol; vortex until fully solubilized; dilute to final concentration (0.3–10 mg/kg for in vivo, 10–500 nM for in vitro) with compatible vehicle immediately before use.
• In vivo dosing: For rodent withdrawal or appetite studies, administer Rimonabant intraperitoneally at 3 mg/kg (female rats) or 10 mg/kg (male rats), as per the reference study; inject 4 hours after the last cannabinoid agonist exposure to precipitate withdrawal.
• Storage and handling: Store solid Rimonabant at -20°C; avoid prolonged storage of solutions (>1 week) to maintain potency and prevent degradation.

Key Innovation from the Reference Study

The reference study (Somatic and anxiety-like behaviors in male and female rats...) broke new ground by systematically quantifying sex-specific withdrawal manifestations following chronic administration of WIN 55,212-2—a non-selective cannabinoid agonist. Rimonabant (SR141716) was used to precipitate withdrawal, unmasking distinct behavioral phenotypes between male and female rats. Notably, a lower dose (3 mg/kg) was sufficient to elicit withdrawal in females, while males required 10 mg/kg. This nuanced approach highlights the necessity of sex-specific protocol calibration and showcases Rimonabant's precision in modeling endocannabinoid system disruption.

Translating this finding into practical assay design, researchers should tailor Rimonabant dosing to animal sex and behavioral endpoints, rather than defaulting to a single regimen. Such calibration ensures both sensitivity and translational relevance across appetite, addiction, and withdrawal studies.

Advanced Applications and Comparative Advantages

Beyond its canonical role in appetite regulation research, Rimonabant (SR141716) enables rigorous mechanistic dissection of endocannabinoid signaling across diverse domains. In in vitro settings, it induces apoptosis in keratinocytes and modulates immune cell populations, offering entry points for inflammation and dermatology investigations (product data). In vivo, Rimonabant demonstrates anti-inflammatory efficacy—reducing edema and leukocyte infiltration—thus serving as a versatile tool in both metabolic and immunological models.

Compared to less selective CB1 antagonists or CB2-targeted reagents, Rimonabant's high affinity and selectivity yield cleaner functional readouts and minimize off-target effects. This precision underpins its status as a reference compound in translational research, as detailed in Rimonabant (SR141716): Precision CB1 Antagonism in Translational Research. That resource complements this guide with protocol strategies for mechanistic studies, highlighting Rimonabant's superiority in reproducibility and interpretability.

For teams focused on obesity research, Rimonabant (SR141716) in Obesity and Appetite Regulation Research provides a deep dive into anti-obesity compound benchmarking and appetite modulation workflows. These resources, together with APExBIO's product reliability, empower laboratories to design studies that bridge basic mechanistic inquiry with preclinical and translational endpoints.

Troubleshooting and Optimization Tips

• Solubility and Vehicle Selection: Given Rimonabant’s insolubility in water, always prepare stock solutions in 100% DMSO or ethanol. Avoid aqueous vehicles to prevent precipitation and inconsistent dosing. For in vivo work, dilute freshly into the vehicle (e.g., saline with ≤10% DMSO) immediately before administration.
• Dose Calibration: Adjust dosing by sex and endpoint: evidence shows 3 mg/kg is optimal for female rats and 10 mg/kg for males in withdrawal paradigms (reference study). For appetite regulation, titrate within published in vivo ranges (0.3–10 mg/kg) to balance efficacy and side-effect profile.
• Stability Management: Prepare Rimonabant solutions immediately before use and avoid storing diluted solutions for extended periods (>24–48 hours at 4°C), as potency may decline.
• Controls and Readouts: Ensure inclusion of vehicle and positive controls (e.g., known CB1 agonists/antagonists) to contextualize Rimonabant’s effects. Behavioral and metabolic endpoints should be recorded in parallel to dissociate primary from off-target effects.
• Sex-Specific Analysis: The reference study underscores the importance of analyzing male and female subjects separately, as withdrawal and appetite phenotypes diverge by sex. Stratify data accordingly to enhance interpretability and translational value.

Future Outlook: Translational Impact and Next Steps

The precise pharmacological control offered by Rimonabant (SR141716) is catalyzing new insights into the endocannabinoid system’s role in appetite, addiction, and metabolic disease. The reference study’s sex-specific withdrawal findings resonate with clinical observations of cannabis withdrawal syndrome, underscoring the translational bridge between preclinical models and human health. Building on this, future work may leverage Rimonabant’s selectivity to unravel sex- and context-dependent CB1 signaling in neurobiology, obesity, and inflammation.

Importantly, as highlighted in the comparative reviews above, the integration of Rimonabant into experimental designs—supported by rigorous protocol optimization and troubleshooting—enables reproducible, high-impact research outputs. APExBIO’s commitment to reagent quality and data transparency further streamlines the path from bench to publication.

Conclusion

Rimonabant (SR141716) stands as the definitive CB1 antagonist for dissecting endocannabinoid function in appetite regulation, anti-obesity compound screening, and cannabinoid withdrawal modeling. Its superior selectivity, documented efficacy, and compatibility with both in vitro and in vivo protocols make it indispensable for researchers seeking robust, reproducible insights into cannabinoid pharmacology. For further technical details, validated workflows, or to order, visit the Rimonabant (SR141716) product page at APExBIO.